234 related articles for article (PubMed ID: 29791862)
1. Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Amaral C; Augusto TV; Tavares-da-Silva E; Roleira FMF; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2018 Oct; 183():51-61. PubMed ID: 29791862
[TBL] [Abstract][Full Text] [Related]
2. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
3. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
4. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
5. Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Augusto TV; Amaral C; Wang Y; Chen S; Almeida CF; Teixeira N; Correia-da-Silva G
Breast Cancer Res Treat; 2021 Nov; 190(2):227-240. PubMed ID: 34498152
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Masri S; Phung S; Wang X; Chen S
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to aromatase inhibitors: where we stand!
Augusto TV; Correia-da-Silva G; Rodrigues CMP; Teixeira N; Amaral C
Endocr Relat Cancer; 2018 May; 25(5):R283-R301. PubMed ID: 29530940
[TBL] [Abstract][Full Text] [Related]
9. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
10. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
[TBL] [Abstract][Full Text] [Related]
11. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
Cepa M; Correia-da-Silva G; da Silva EJ; Roleira FM; Borges M; Teixeira NA
BMC Cell Biol; 2008 Jul; 9():41. PubMed ID: 18652661
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and autophagy in breast cancer cells following exemestane treatment.
Amaral C; Borges M; Melo S; da Silva ET; Correia-da-Silva G; Teixeira N
PLoS One; 2012; 7(8):e42398. PubMed ID: 22912703
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
15. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
16. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Yamamoto Y; Ishikawa T; Hozumi Y; Ikeda M; Iwata H; Yamashita H; Toyama T; Chishima T; Saji S; Yamamoto-Ibusuki M; Iwase H
BMC Cancer; 2013 May; 13():239. PubMed ID: 23679192
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Masri S; Lui K; Phung S; Ye J; Zhou D; Wang X; Chen S
Breast Cancer Res Treat; 2009 Aug; 116(3):461-70. PubMed ID: 18677558
[TBL] [Abstract][Full Text] [Related]
19. Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Amaral C; Lopes A; Varela CL; da Silva ET; Roleira FM; Correia-da-Silva G; Teixeira N
Int J Biochem Cell Biol; 2015 Dec; 69():183-95. PubMed ID: 26515125
[TBL] [Abstract][Full Text] [Related]
20. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
